REGENERON PHARMACEUTICALS (REGN) Stock Price, Quote, News and Overview
NASDAQ:REGN - Nasdaq - US75886F1075 - Common Stock - Currency: USD
REGN Quote, Performance and Key Statistics
700.33
+4.31 (+0.62%)
The current stock price of REGN is 700.33 USD. In the past month the price increased by 0.82%. In the past year, price decreased by -28.63%.
REGN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.86 | 16.12B |
Related stock screener links
About REGN
Company Profile
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. The company is headquartered in Tarrytown, New York and currently employs 13,450 full-time employees. The firm invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The firm helps in accelerating and improving the traditional drug development process through its VelociSuite technologies, such as VelocImmune, which uses genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center. Its marketed products include EYLEA (aflibercept) Injection; Dupixent (dupilumab) Injection; Libtayo (cemiplimab) Injection; Praluent (alirocumab) Injection; Kevzara (sarilumab) Injection, and others.
Company Info
REGENERON PHARMACEUTICALS
777 Old Saw Mill River Road
Tarrytown NEW YORK 10591 US
CEO: Leonard S. Schleifer
Employees: 13926
Company Website: https://www.regeneron.com/
Investor Relations: https://investor.regeneron.com/
Phone: 17813705000
REGENERON PHARMACEUTICALS / REGN FAQ
What is the stock price of REGENERON PHARMACEUTICALS today?
The current stock price of REGN is 700.33 USD. The price increased by 0.62% in the last trading session.
What is the ticker symbol for REGENERON PHARMACEUTICALS stock?
The exchange symbol of REGENERON PHARMACEUTICALS is REGN and it is listed on the Nasdaq exchange.
On which exchange is REGN stock listed?
REGN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for REGENERON PHARMACEUTICALS stock?
34 analysts have analysed REGN and the average price target is 943.27 USD. This implies a price increase of 34.69% is expected in the next year compared to the current price of 700.33. Check the REGENERON PHARMACEUTICALS stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is REGENERON PHARMACEUTICALS worth?
REGENERON PHARMACEUTICALS (REGN) has a market capitalization of 76.56B USD. This makes REGN a Large Cap stock.
How many employees does REGENERON PHARMACEUTICALS have?
REGENERON PHARMACEUTICALS (REGN) currently has 13926 employees.
What are the support and resistance levels for REGENERON PHARMACEUTICALS (REGN) stock?
REGENERON PHARMACEUTICALS (REGN) has a support level at 672.97 and a resistance level at 705.16. Check the full technical report for a detailed analysis of REGN support and resistance levels.
Is REGENERON PHARMACEUTICALS (REGN) expected to grow?
The Revenue of REGENERON PHARMACEUTICALS (REGN) is expected to grow by 3.48% in the next year. Check the estimates tab for more information on the REGN EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy REGENERON PHARMACEUTICALS (REGN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of REGN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of REGN, evaluating the profitability, health, valuation and growth aspects
- REGENERON PHARMACEUTICALS (REGN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- REGENERON PHARMACEUTICALS (REGN) Sales and EPS estimates to see what analysts future expectations are.
- REGENERON PHARMACEUTICALS (REGN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- REGENERON PHARMACEUTICALS (REGN) Insider and Institutional Ownership to learn about the owners and their transactions.
- REGENERON PHARMACEUTICALS (REGN) Stock Chart to make your own analysis
- REGENERON PHARMACEUTICALS (REGN) Latest news and press-releases to stay up to date.
Does REGENERON PHARMACEUTICALS (REGN) stock pay dividends?
REGENERON PHARMACEUTICALS (REGN) has a dividend yield of 0.51%. The yearly dividend amount is currently 0. Check the full fundamental report for a detailed analysis of REGN dividend history, reliability and sustainability.
When does REGENERON PHARMACEUTICALS (REGN) report earnings?
REGENERON PHARMACEUTICALS (REGN) will report earnings on 2025-04-30, before the market open.
What is the Price/Earnings (PE) ratio of REGENERON PHARMACEUTICALS (REGN)?
The PE ratio for REGENERON PHARMACEUTICALS (REGN) is 15.34. This is based on the reported non-GAAP earnings per share of 45.64 and the current share price of 700.33 USD. Check the full fundamental report for a full analysis of the valuation metrics for REGN.
What is the Short Interest ratio of REGENERON PHARMACEUTICALS (REGN) stock?
The outstanding short interest for REGENERON PHARMACEUTICALS (REGN) is 2.07% of its float. Check the ownership tab for more information on the REGN short interest.
REGN Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to REGN. When comparing the yearly performance of all stocks, REGN is a bad performer in the overall market: 83.09% of all stocks are doing better.
REGN Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to REGN. REGN scores excellent points on both the profitability and health parts. This is a solid base for a good stock.
REGN Financial Highlights
Over the last trailing twelve months REGN reported a non-GAAP Earnings per Share(EPS) of 45.64. The EPS increased by 4.25% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 31.07% | ||
| ROA | 11.69% | ||
| ROE | 15.03% | ||
| Debt/Equity | 0.09 |
REGN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 78% to REGN. The Buy consensus is the average rating of analysts ratings from 34 analysts.
For the next year, analysts expect an EPS growth of -4.81% and a revenue growth 3.48% for REGN